Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00850096 · ClinicalTrials.gov registry record · Phase 2

Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus

A Phase 2 study of Type 2 Diabetes, sponsored by CPEX Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
94
Enrollment target
20
Study locations

NCT00850096: Completed Phase 2 study of Type 2 Diabetes, sponsored by CPEX Pharmaceuticals.

NCT00850096 is a Phase 2 study of Type 2 Diabetes that has completed, run by CPEX Pharmaceuticals. The registered enrollment target is 94 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00850096, a Phase 2 study of Type 2 Diabetes, has completed, sponsored by CPEX Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
94 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is: * To assess the efficacy of Nasulin vs. placebo as indicated by time spent in euglycemia, assessed by continuous glucose monitoring data and serum fructosamine levels in patient volunteers with Type 2 Diabetes. * To asses the safety and tolerability of Nauslin at 50 IU and 100IU doses in patient volunteers with Type 2 Diabetes

Conditions Studied

Type 2 Diabetes

Interventions

  • OTHER Placebo for Nasulin
  • DRUG Nasulin

Study Locations (20)

California

  • AMCR Institute, Inc - Escondido
  • Scripps Whittier Diabetes Clinic - La Jolla
  • Mills-Penninsula Health Services; Dorothy & Frank Diabetes Inst. - San Mateo
  • Diablo Clinical Research - Walnut Creek

Florida

  • Clinical Research of West Florida - Clearwater
  • University of Miami Diabetes Research Institute - Miami
  • Metabolic Research Institute - West Palm Beach

North Carolina

  • Mountain Diabetes and Endocrine Center - Asheville
  • ECU Diabetes Research Center - Greenville
  • Physician's East PA - Greenville

Texas

  • Texas Diabetes and Endocrinology - Austin
  • University of Texas; Southwestern Medical Center - Dallas

Arizona

  • Radiant Research - Chandler

Colorado

  • Barbara Davis Center - Aurora

Georgia

  • Atlanta Diabetes Associates - Atlanta

Hawaii

  • East-West Medical Research Institute - Honolulu

Trial Details

FieldValue
Enrollment Target 94 participants
Start Date 2009-01
Est. Completion 2010-03
Phase Phase 2

Sponsor

CPEX Pharmaceuticals

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00850096

The ClinicalTrials.gov registry entry for NCT00850096 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (91% lower). The listed sponsor is CPEX Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo for Nasulin is the first listed.

NCT00850096 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, North Carolina.

Frequently Asked Questions

What is clinical trial NCT00850096 about?

NCT00850096 is a clinical study titled "Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus". The purpose of this study is: * To assess the efficacy of Nasulin vs. placebo as indicated by time spent in euglycemia, assessed by continuous glucose monitoring data and serum fructosamine levels in patient volunteers with Type 2 Diabetes. * To asses the safety and tolerability of Nauslin at 50 IU...

What is the current status of trial NCT00850096?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2009-01. Estimated completion is 2010-03.

What conditions does trial NCT00850096 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT00850096?

The interventions under investigation include: Placebo for Nasulin (OTHER), Nasulin (DRUG).

Who is sponsoring clinical trial NCT00850096?

This trial is sponsored by CPEX Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00850096 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.